Publications by authors named "Bjoern Rueter"

Claim this Profile
U
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Andrew F Berdel, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Röllig, Bjoern Rueter

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
Bhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, Xiaokui Mo, Donna Bucci, Bjoern Rueter

Oncotarget· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Sumithira Vasu, Shun He, Carolyn Cheney, Bhavani Gopalakrishnan, Rajeswaran Mani, Bjoern Rueter

Blood· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis